Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.07 | 0.05 | -0.01 |
| FCF Yield | -3.90% | -6.53% | -19.13% | -11.02% |
| EV / EBITDA | -12.47 | -18.81 | -6.31 | -2.90 |
| Quality | ||||
| ROIC | -8.38% | -5.75% | -7.56% | -7.78% |
| Gross Margin | 78.95% | 80.97% | 75.07% | 78.06% |
| Cash Conversion Ratio | 0.39 | 0.67 | 0.57 | 0.39 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.92% | -10.87% | -15.25% | -21.96% |
| Free Cash Flow Growth | 21.56% | 31.87% | -5.34% | 52.66% |
| Safety | ||||
| Net Debt / EBITDA | -3.46 | -5.03 | -1.79 | 0.65 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -1,102.19 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -68.15 | -64.82 | -33.56 | -86.46 |